A copy of the poster will be made available on the Company’s website following the presentation.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
This news release contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations and assumptions as of the date of this presentation, and actual results may differ materially from those in these forward-looking statements as a result of various factors, including many which are beyond INSYS’ control.
Such factors include, but are not limited to risks regarding: the expenses, impact and potential outcomes of pending claims, litigation and other legal proceedings, including the completion of the settlement in principle with the DOJ; INSYS' indemnification obligations for former executives; the heightened attention on the use of opioids; INSYS' ability to secure additional funding as needed; INSYS' ability to consummate a strategic alternative for its portfolio of opioid-related assets; INSYS’ ability to continue as a going concern; INSYS' ability to commercialize products successfully; INSYS’ ability to successfully manage its commercial relationships and sales infrastructure; INSYS’ ability to obtain anticipated governmental or regulatory approvals; INSYS’ failure to comply with post-approval regulatory and governmental requirements; the actual sales potential and opportunity of identified markets; and INSYS’ ability to realize the expectations of its pipeline and product candidate plans and timelines. For a further description of these and other risks facing INSYS, please see the risk factors described in the company's filings with the
|CONTACT:||Investor Relations & Corporate Communications|
|Jackie Marcus or Chris Hodges|
|Alpha IR Group|
Source: INSYS Therapeutics, Inc.